Testimony: Restricting Youth Access to Nicotine and Tobacco Products
Delivered to Philadelphia City Council
Population Health
Policy
Comment: Patient Focused Drug Development: Methodologic and Other Challenges Related to Patient Experience Data
Submitted to the Food and Drug Administration and Department of Health and Human Services
Print:
On December 18, 2024, LDI Senior Fellow Sean Hennessy, PharmD, PhD submitted a comment in response to a Request for Comments from the U.S Food and Drug Administration and U.S. Department of Health and Human Services. The request sought input regarding methodological challenges related to data on patient experience.
As an expert in pharmacoepidemiology, the study of the health effects of drugs and other medical products in populations, Dr. Hennessy provides 10 suggestions for improving the use of patient experience data in patient focused drug development.
More on Policy at LDI
Briefing: Nursing Home Staffing Mandate and Resident Outcomes
Presented to Staff of U.S. Senate Committee on Finance
Comment: Studies from Penn LDI on Medicare Post-Acute Care
Submitted to the U.S. Committee on Ways & Means Subcommittee on Health
Briefing: Health Implications of the Supplemental Nutrition Assistance Program (SNAP)
Presented to Staff of Rep. GT Thompson (R-PA)
Testimony: The Effectiveness and Potential Expansion of Mobile Mental Health Units
Delivered to Philadelphia City Council
Testimony: Elevated Lead Levels in PA School Buildings
Delivered to the Pennsylvania House Majority Policy Committee